SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation

Takafumi Toyohara, Takehiro Suzuki, Ryo Morimoto, Yasutoshi Akiyama, Tomokazu Souma, Hiromi O. Shiwaku, Yoichi Takeuchi, Eikan Mishima, Michiaki Abe, Masayuki Tanemoto, Satohiro Masuda, Hiroaki Kawano, Koji Maemura, Masaaki Nakayama, Hiroshi Sato, Tsuyoshi Mikkaichi, Hiroaki Yamaguchi, Shigefumi Fukui, Yoshihiro Fukumoto, Hiroaki ShimokawaKen Ichi Inui, Tetsuya Terasaki, Junichi Goto, Sadayoshi Ito, Takanori Hishinuma, Isabelle Rubera, Michel Tauc, Yoshiaki Fujii-Kuriyama, Hikaru Yabuuchi, Yoshinori Moriyama, Tomoyoshi Soga, Takaaki Abe

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Hypertension in patients with chronic kidney disease (CKD) strongly associates with cardiovascular events. Among patients with CKD, reducing the accumulation of uremic toxins may protect against the development of hypertension and progression of renal damage, but there are no established therapies to accomplish this. Here, overexpression of human kidney-specific organic anion transporter SLCO4C1 in rat kidney reduced hypertension, cardiomegaly, and inflammation in the setting of renal failure. In addition, SLCO4C1 overexpression decreased plasma levels of the uremic toxins guanidino succinate, asymmetric dimethylarginine, and the newly identified trans-aconitate. We found that xenobiotic responsive element core motifs regulate SLCO4C1 transcription, and various statins, which act as inducers of nuclear aryl hydrocarbon receptors, upregulate SLCO4C1 transcription. Pravastatin, which is cardioprotective, increased the clearance of asymmetric dimethylarginine and trans-aconitate in renal failure. These data suggest that drugs that upregulate SLCO4C1 may have therapeutic potential for patients with CKD.

Original languageEnglish
Pages (from-to)2546-2555
Number of pages10
JournalJournal of the American Society of Nephrology
Volume20
Issue number12
DOIs
Publication statusPublished - 2009 Dec 1

Fingerprint

Renal Hypertension
Aconitic Acid
Chronic Renal Insufficiency
Inflammation
Renal Insufficiency
Up-Regulation
Organic Anion Transporters
Hypertension
Kidney
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Aryl Hydrocarbon Receptors
Pravastatin
Cardiomegaly
Succinic Acid
Xenobiotics
Therapeutics
Pharmaceutical Preparations
N,N-dimethylarginine

ASJC Scopus subject areas

  • Nephrology

Cite this

Toyohara, T., Suzuki, T., Morimoto, R., Akiyama, Y., Souma, T., Shiwaku, H. O., ... Abe, T. (2009). SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. Journal of the American Society of Nephrology, 20(12), 2546-2555. https://doi.org/10.1681/ASN.2009070696

SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. / Toyohara, Takafumi; Suzuki, Takehiro; Morimoto, Ryo; Akiyama, Yasutoshi; Souma, Tomokazu; Shiwaku, Hiromi O.; Takeuchi, Yoichi; Mishima, Eikan; Abe, Michiaki; Tanemoto, Masayuki; Masuda, Satohiro; Kawano, Hiroaki; Maemura, Koji; Nakayama, Masaaki; Sato, Hiroshi; Mikkaichi, Tsuyoshi; Yamaguchi, Hiroaki; Fukui, Shigefumi; Fukumoto, Yoshihiro; Shimokawa, Hiroaki; Inui, Ken Ichi; Terasaki, Tetsuya; Goto, Junichi; Ito, Sadayoshi; Hishinuma, Takanori; Rubera, Isabelle; Tauc, Michel; Fujii-Kuriyama, Yoshiaki; Yabuuchi, Hikaru; Moriyama, Yoshinori; Soga, Tomoyoshi; Abe, Takaaki.

In: Journal of the American Society of Nephrology, Vol. 20, No. 12, 01.12.2009, p. 2546-2555.

Research output: Contribution to journalArticle

Toyohara, T, Suzuki, T, Morimoto, R, Akiyama, Y, Souma, T, Shiwaku, HO, Takeuchi, Y, Mishima, E, Abe, M, Tanemoto, M, Masuda, S, Kawano, H, Maemura, K, Nakayama, M, Sato, H, Mikkaichi, T, Yamaguchi, H, Fukui, S, Fukumoto, Y, Shimokawa, H, Inui, KI, Terasaki, T, Goto, J, Ito, S, Hishinuma, T, Rubera, I, Tauc, M, Fujii-Kuriyama, Y, Yabuuchi, H, Moriyama, Y, Soga, T & Abe, T 2009, 'SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation', Journal of the American Society of Nephrology, vol. 20, no. 12, pp. 2546-2555. https://doi.org/10.1681/ASN.2009070696
Toyohara, Takafumi ; Suzuki, Takehiro ; Morimoto, Ryo ; Akiyama, Yasutoshi ; Souma, Tomokazu ; Shiwaku, Hiromi O. ; Takeuchi, Yoichi ; Mishima, Eikan ; Abe, Michiaki ; Tanemoto, Masayuki ; Masuda, Satohiro ; Kawano, Hiroaki ; Maemura, Koji ; Nakayama, Masaaki ; Sato, Hiroshi ; Mikkaichi, Tsuyoshi ; Yamaguchi, Hiroaki ; Fukui, Shigefumi ; Fukumoto, Yoshihiro ; Shimokawa, Hiroaki ; Inui, Ken Ichi ; Terasaki, Tetsuya ; Goto, Junichi ; Ito, Sadayoshi ; Hishinuma, Takanori ; Rubera, Isabelle ; Tauc, Michel ; Fujii-Kuriyama, Yoshiaki ; Yabuuchi, Hikaru ; Moriyama, Yoshinori ; Soga, Tomoyoshi ; Abe, Takaaki. / SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. In: Journal of the American Society of Nephrology. 2009 ; Vol. 20, No. 12. pp. 2546-2555.
@article{8211d3bee42b4e76bd0c1fbc60118417,
title = "SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation",
abstract = "Hypertension in patients with chronic kidney disease (CKD) strongly associates with cardiovascular events. Among patients with CKD, reducing the accumulation of uremic toxins may protect against the development of hypertension and progression of renal damage, but there are no established therapies to accomplish this. Here, overexpression of human kidney-specific organic anion transporter SLCO4C1 in rat kidney reduced hypertension, cardiomegaly, and inflammation in the setting of renal failure. In addition, SLCO4C1 overexpression decreased plasma levels of the uremic toxins guanidino succinate, asymmetric dimethylarginine, and the newly identified trans-aconitate. We found that xenobiotic responsive element core motifs regulate SLCO4C1 transcription, and various statins, which act as inducers of nuclear aryl hydrocarbon receptors, upregulate SLCO4C1 transcription. Pravastatin, which is cardioprotective, increased the clearance of asymmetric dimethylarginine and trans-aconitate in renal failure. These data suggest that drugs that upregulate SLCO4C1 may have therapeutic potential for patients with CKD.",
author = "Takafumi Toyohara and Takehiro Suzuki and Ryo Morimoto and Yasutoshi Akiyama and Tomokazu Souma and Shiwaku, {Hiromi O.} and Yoichi Takeuchi and Eikan Mishima and Michiaki Abe and Masayuki Tanemoto and Satohiro Masuda and Hiroaki Kawano and Koji Maemura and Masaaki Nakayama and Hiroshi Sato and Tsuyoshi Mikkaichi and Hiroaki Yamaguchi and Shigefumi Fukui and Yoshihiro Fukumoto and Hiroaki Shimokawa and Inui, {Ken Ichi} and Tetsuya Terasaki and Junichi Goto and Sadayoshi Ito and Takanori Hishinuma and Isabelle Rubera and Michel Tauc and Yoshiaki Fujii-Kuriyama and Hikaru Yabuuchi and Yoshinori Moriyama and Tomoyoshi Soga and Takaaki Abe",
year = "2009",
month = "12",
day = "1",
doi = "10.1681/ASN.2009070696",
language = "English",
volume = "20",
pages = "2546--2555",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "12",

}

TY - JOUR

T1 - SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation

AU - Toyohara, Takafumi

AU - Suzuki, Takehiro

AU - Morimoto, Ryo

AU - Akiyama, Yasutoshi

AU - Souma, Tomokazu

AU - Shiwaku, Hiromi O.

AU - Takeuchi, Yoichi

AU - Mishima, Eikan

AU - Abe, Michiaki

AU - Tanemoto, Masayuki

AU - Masuda, Satohiro

AU - Kawano, Hiroaki

AU - Maemura, Koji

AU - Nakayama, Masaaki

AU - Sato, Hiroshi

AU - Mikkaichi, Tsuyoshi

AU - Yamaguchi, Hiroaki

AU - Fukui, Shigefumi

AU - Fukumoto, Yoshihiro

AU - Shimokawa, Hiroaki

AU - Inui, Ken Ichi

AU - Terasaki, Tetsuya

AU - Goto, Junichi

AU - Ito, Sadayoshi

AU - Hishinuma, Takanori

AU - Rubera, Isabelle

AU - Tauc, Michel

AU - Fujii-Kuriyama, Yoshiaki

AU - Yabuuchi, Hikaru

AU - Moriyama, Yoshinori

AU - Soga, Tomoyoshi

AU - Abe, Takaaki

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Hypertension in patients with chronic kidney disease (CKD) strongly associates with cardiovascular events. Among patients with CKD, reducing the accumulation of uremic toxins may protect against the development of hypertension and progression of renal damage, but there are no established therapies to accomplish this. Here, overexpression of human kidney-specific organic anion transporter SLCO4C1 in rat kidney reduced hypertension, cardiomegaly, and inflammation in the setting of renal failure. In addition, SLCO4C1 overexpression decreased plasma levels of the uremic toxins guanidino succinate, asymmetric dimethylarginine, and the newly identified trans-aconitate. We found that xenobiotic responsive element core motifs regulate SLCO4C1 transcription, and various statins, which act as inducers of nuclear aryl hydrocarbon receptors, upregulate SLCO4C1 transcription. Pravastatin, which is cardioprotective, increased the clearance of asymmetric dimethylarginine and trans-aconitate in renal failure. These data suggest that drugs that upregulate SLCO4C1 may have therapeutic potential for patients with CKD.

AB - Hypertension in patients with chronic kidney disease (CKD) strongly associates with cardiovascular events. Among patients with CKD, reducing the accumulation of uremic toxins may protect against the development of hypertension and progression of renal damage, but there are no established therapies to accomplish this. Here, overexpression of human kidney-specific organic anion transporter SLCO4C1 in rat kidney reduced hypertension, cardiomegaly, and inflammation in the setting of renal failure. In addition, SLCO4C1 overexpression decreased plasma levels of the uremic toxins guanidino succinate, asymmetric dimethylarginine, and the newly identified trans-aconitate. We found that xenobiotic responsive element core motifs regulate SLCO4C1 transcription, and various statins, which act as inducers of nuclear aryl hydrocarbon receptors, upregulate SLCO4C1 transcription. Pravastatin, which is cardioprotective, increased the clearance of asymmetric dimethylarginine and trans-aconitate in renal failure. These data suggest that drugs that upregulate SLCO4C1 may have therapeutic potential for patients with CKD.

UR - http://www.scopus.com/inward/record.url?scp=72049086464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72049086464&partnerID=8YFLogxK

U2 - 10.1681/ASN.2009070696

DO - 10.1681/ASN.2009070696

M3 - Article

C2 - 19875811

AN - SCOPUS:72049086464

VL - 20

SP - 2546

EP - 2555

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 12

ER -